Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
Open accessAbstract
HYPOTHESIS: The tumor micro-environment and especially the different macrophage phenotypes appear to be of great influence on the behavior of multiple tumor types. M1 skewed macrophages possess anti-tumoral capacities, while the M2 polarized macrophages have pro-tumoral capacities. We analyzed if the macrophage count and the M2 to total macrophage ratio is a discriminative marker for outcome after surgery in malignant pleural mesothelioma (MPM) and studied the prognostic value of these immunological cells. METHODS: 8 MPM patients who received induction chemotherapy and surgical treatment were matched on age, sex, tumor histology, TNM stage and EORTC score with 8 patients who received chemotherapy only. CD8 positive T-cells and the total macrophage count, using the CD68 pan-macrophage marker, and CD163 positive M2 macrophage count were determined in tumor specimens prior to treatment. RESULTS: The number of CD68 and CD163 cells was comparable between the surgery and the non-surgery group, and was not related to overall survival (OS) in both the surgery and non-surgery group. However, the CD163/CD68 ratio did correlate with OS in both in the total patient group (Pearson r -0.72, p<0.05). No correlation between the number of CD8 cells and prognosis was found. CONCLUSIONS: The total number of macrophages in tumor tissue did not correlate with OS in both groups, however, the CD163/CD68 ratio correlates with OS in the total patient group. Our data revealed that the CD163/CD68 ratio is a potential prognostic marker in epithelioid mesothelioma patients independent of treatment but cannot be used as a predictive marker for outcome after surgery.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most tumour-associated macrophages (TAM) adopt an M2-type phenotype, and their presence correlates with poor prognosis.
“Most tumour-associated macrophages (TAM) adopt an M2-type phenotype, and their presence correlates with a poor prognosis [199,200].”
From Superoxide Anion Chemistry—Its Role at the Core of the Innate Immunity (2023) · cites this paper as [200]
In cancer, M1 macrophages have anti-tumour functions, while M2 macrophages support angiogenesis, invasion and metastasis of neoplastic cells.
“In cancer, M1 macrophages have anti-tumour functions, while M2 macrophages support angiogenesis, invasion and metastasis of neoplastic cells.”
From Superoxide Anion Chemistry—Its Role at the Core of the Innate Immunity (2023) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · see citing works
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060 · see citing works
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · see citing works
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · see citing works
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,678 · see citing works
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484 · see citing works
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,324 · see citing works
Differential macrophage programming in the tumor microenvironment
Ruffell, B., Affara, N. I., & Coussens, L. M. (2012) · Trends in Immunology · doi:10.1016/j.it.2011.12.001 · Cited by 855 · see citing works
“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792 · see citing works
Medrek, C., Pontén, F., Jirström, K., & Leandersson, K. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-306 · Cited by 648 · see citing works
Scherpereel, A., Astoul, P. J., Baas, P., Berghmans, T., Clayson, H., Vuyst, P. D., Dienemann, H., Galateau-Sallé, F., Hennequin, C., Hillerdal, G., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00063109 · Cited by 644 · see citing works
van Meerbeeck, J. P., Gaafar, R. M., Manegold, C., van Klaveren, R. J., Marck, E. A. V., Vincent, M. D., Legrand, C., Bottomley, A., Debruyne, C., & Giaccone, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.20005.14.589 · Cited by 617 · see citing works
Flores, R. M., Pass, H. I., Seshan, V., Dycoco, J., Zakowski, M. F., Carbone, M., Bains, M. S., & Rusch, V. W. (2008) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.10.054 · Cited by 614 · see citing works
Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549 · see citing works
Edin, S., Wikberg, M. L., Dahlin, A. M., Rutegård, M., Öberg, Å., Oldenborg, P., & Palmqvist, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047045 · Cited by 486 · see citing works
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I. I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 486 · see citing works
Identification and manipulation of tumor associated macrophages in human cancers
Heusinkveld, M., & van der Burg, S. H. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-216 · Cited by 432 · see citing works
Bremnes, R. M., Al-Shibli, K. I., Dønnem, T., Sirera, R., Al‐Saad, S., Andersen, S., Stenvold, H., Camps, C., & Busund, L. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182037b76 · Cited by 369 · see citing works
Tumour macrophages as potential targets of bisphosphonates
Rogers, T. L., & Holen, I. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-177 · Cited by 329 · see citing works
Anti‐tumour strategies aiming to target tumour‐associated macrophages
Tang, X., Mo, C., Wang, Y., Wei, D., & Xiao, H. (2012) · Immunology · doi:10.1111/imm.12023 · Cited by 278 · see citing works
Lan, C., Huang, X., Lin, S., Huang, H., Cai, Q.-C., Wan, T., Lu, J., & Liu, J. (2013) · Technology in Cancer Research & Treatment · doi:10.7785/tcrt.2012.500312 · Cited by 228 · see citing works
IFN-γ-Stimulated Neutrophils Suppress Lymphocyte Proliferation through Expression of PD-L1
de Kleijn, S., Langereis, J. D., Leentjens, J., Kox, M., Netea, M. G., Koenderman, L., Ferwerda, G., Pickkers, P., & Hermans, P. W. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072249 · Cited by 203 · see citing works
Blockade of a Chemokine, CCL2, Reduces Chronic Colitis-Associated Carcinogenesis in Mice
Popivanova, B. K., Kostadinova, F. I., Furuichi, K., Shamekh, M. M., Kondo, T., Wada, T., Egashira, K., & Mukaida, N. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1451 · Cited by 201 · see citing works
An antiinflammatory role for IKKβ through the inhibition of “classical” macrophage activation
Fong, C. H.-Y., Bébien, M., Didierlaurent, A. M., Nebauer, R., Hussell, T., Broide, D. H., Karin, M., & Lawrence, T. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080124 · Cited by 197 · see citing works
Myeloid Cells in the Tumor Microenvironment: Modulation of Tumor Angiogenesis and Tumor Inflammation
Schmid, M. C., & Varner, J. A. (2010) · Journal of Oncology · doi:10.1155/2010/201026 · Cited by 181 · see citing works
Yamada, N., Oizumi, S., Kikuchi, E., Shinagawa, N., Konishi-Sakakibara, J., 伊志嶺, 篤., Aoe, K., Gemba, K., Kishimoto, T., Torigoe, T., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0881-6 · Cited by 169 · see citing works
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
Hegmans, J. P., Hemmes, A., Hammad, H., Boon, L., Hoogsteden, H. C., & Lambrecht, B. N. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00135305 · Cited by 160 · see citing works
Self-citationImpact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
Anraku, M., Cunningham, K. S., Yun, Z., Tsao, M., Li, Z., Keshavjee, S. H., Johnston, M. R., & de Perrot, M. E. (2008) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.10.026 · Cited by 153 · see citing works
Alexander, H. R., Bartlett, D. L., Pingpank, J. F., Libutti, S. K., Royal, R. E., Hughes, M. S., Holtzman, M. P., Hanna, N. N., Turner, K. M., Beresneva, T., et al. (2013) · Surgery · doi:10.1016/j.surg.2013.01.001 · Cited by 150 · see citing works
Fridlender, Z. G., Kapoor, V., Buchlis, G., Cheng, G., Sun, J., Wang, L. S., Singhal, S. K., Snyder, L. A., & Albelda, S. Μ. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0080oc · Cited by 147 · see citing works
Buhtoiarov, I. N., Sondel, P. M., Wigginton, J. M., Buhtoiarova, T. N., Yanke, E. M., Mahvi, D. A., & Rakhmilevich, A. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03357.x · Cited by 143 · see citing works
Niino, D., Komohara, Y., Murayama, T., Aoki, R., Kimura, Y., Hashikawa, K., Kiyasu, J., Takeuchi, M., Suefuji, N., Sugita, Y., et al. (2010) · Pathology International · doi:10.1111/j.1440-1827.2010.02514.x · Cited by 126 · see citing works
Tanaka, S., Choe, N., Hemenway, D. R., Zhu, S., Matalon, S., & Kagan, E. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3169 · Cited by 121 · see citing works
Circulating and Tumor-Infiltrating Myeloid Cells Predict Survival in Human Pleural Mesothelioma
Burt, B. M., Rodig, S. J., Tilleman, T. R., Elbardissi, A. W., Bueno, R., & Sugarbaker, D. J. (2011) · Cancer · doi:10.1002/cncr.26143 · Cited by 115 · see citing works
Fennell, D. A., Parmar, A., Shamash, J., Evans, M. T., Sheaff, M. T., Sylvester, R. J., Dhaliwal, K., Gower, N. H., Steele, J. P. C., & Rudd, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.050 · Cited by 109 · see citing works
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
Veltman, J. D., Lambers, M. E. H., van Nimwegen, M., Hendriks, R. W., Hoogsteden, H. C., Hegmans, J. P., & Aerts, J. G. J. V. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605814 · Cited by 104 · see citing works
Self-citationPantano, F., Berti, P., Guida, F., Perrone, G., Vincenzi, B., Amato, M., Righi, D., Dell'Aquila, E., Graziano, F., Catalano, V., et al. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12109 · Cited by 94 · see citing works
Correlations of Tumor-associated Macrophage Subtypes with Liver Metastases of Colorectal Cancer
Cui, Y., Li, H., Zhou, H.-Y., Zhang, T., & Li, Q. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.2.1003 · Cited by 91 · see citing works
Four-Gene Expression Ratio Test for Survival in Patients Undergoing Surgery for Mesothelioma
Gordon, G. J., Dong, L., Yeap, B. Y., Richards, W. G., Glickman, J. N., Edenfield, H., Mani, M., Colquitt, R. B., Maulik, G., Oss, B. V., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp061 · Cited by 89 · see citing works
Kaimala, S., Mohamed, Y., Nader, N., Issac, J. M., Elkord, E., Chouaib, S., Fernandez-Cabezudo, M., & al-Ramadi, B. (2014) · Cancer Immunology and Immunotherapy · doi:10.1007/s00262-014-1543-x · Cited by 77 · see citing works
Suzuki, K., Kadota, K., Sima, C. S., Sadelain, M., Rusch, V. W., Travis, W. D., & Adusumilli, P. S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1073-8 · Cited by 76 · see citing works
Herwig‐Carl, M. C., Bergstrom, C. S., Wells, J. R., Höller, T., & Grossniklaus, H. E. (2012) · Experimental Eye Research · doi:10.1016/j.exer.2012.11.012 · Cited by 74 · see citing works
Tumor-associated macrophages in thoracic malignancies
Lievense, L. A., Bezemer, K., Aerts, J. G. J. V., & Hegmans, J. P. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.017 · Cited by 60 · see citing works
Self-citationExpression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma
Soini, Y., Kahlos, K., Puhakka, A. M., Lakari, E., Säily, M., Pääkkö, P. K., & Kinnula, V. L. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1384 · Cited by 45 · see citing works
Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
Chuang, C.-M., Monie, A., Hung, C., & Wu, T. ‐. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-32 · Cited by 44 · see citing works
Becker, M. W., Müller, C. B., Bastiani, M. A. D., & Klamt, F. (2014) · PubMed · doi:10.14670/hh-29.21 · Cited by 43 · see citing works
Malignant Pleural Mesothelioma
Haas, A. R., & Sterman, D. H. (2013) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2012.12.005 · Cited by 40 · see citing works
New Roads Open Up for Implementing Immunotherapy in Mesothelioma
Cornelissen, R., Heuvers, M. E., Maat, A. P. W. M., Hendriks, R. W., Hoogsteden, H. C., Aerts, J. G. J. V., & Hegmans, J. P. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/927240 · Cited by 23 · see citing works
Self-citationMacrophages: Cancer Therapy's Double-Edged Sword
Brower, V. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs235 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Bueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., Rienzo, A. D., Modrusan, Z. D., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 920 · see citing works
Physical and mechanical regulation of macrophage phenotype and function
McWhorter, F. Y., Davis, C. T., & Liu, W. F. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1796-8 · Cited by 437 · see citing works
Superoxide Anion Chemistry—Its Role at the Core of the Innate Immunity
Andrés, C. M. C., Pérez de la Lastra, J. M., Andrés Juan, C., Plou, F. J., & Pérez-Lebeña, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031841 · Cited by 342 · see citing works
Bianchi, M. E., Crippa, M. P., Manfredi, A. A., Mezzapelle, R., Rovere, P. Q., & Vénéreau, E. (2017) · Immunological Reviews · doi:10.1111/imr.12601 · Cited by 327 · see citing works
Novel Insights into Mesothelioma Biology and Implications for Therapy
Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.42 · Cited by 324 · see citing works
Self-citationBecht, É., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent‐Puig, P., Zucman‐Rossi, J., Dieu‐Nosjean, M., Sautès‐Fridman, C., & Fridman, W. H. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 213 · see citing works
Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
Conniot, J., Silva, J. M., Fernandes, J. G., Silva, L. C., Gaspar, R. S., Brocchini, S., Florindo, H. F., & Barata, T. S. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00105 · Cited by 200 · see citing works
Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas
Dancsok, A. R., Gao, D., Lee, A. F., Steigen, S. E., Blay, J., Thomas, D. M., Maki, R. G., Nielsen, T. O., & Demicco, E. G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1747340 · Cited by 181 · see citing works
Napolitano, A., Pellegrini, L., Dey, A., LARSON, D. L., Tanji, M., Flores, E. G., Kendrick, B., Lapid, D. J., Powers, A. A., Kanodia, S., et al. (2015) · Oncogene · doi:10.1038/onc.2015.243 · Cited by 158 · see citing works
Dammeijer, F. F., Lievense, L. A., Kaijen-Lambers, M. E. H., van Nimwegen, M., Bezemer, K., Hegmans, J. P., van Hall, T., Hendriks, R. W., & Aerts, J. G. J. V. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0309 · Cited by 144 · see citing works
Self-citationHong, D. S., Postow, M. A., Chmielowski, B., Sullivan, R. J., Patnaik, A., Cohen, E. E. W., Shapiro, G. I., Steuer, C. E., Gutierrez, M. E., Yeckes-Rodin, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3313 · Cited by 111 · see citing works
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
Castelletti, L., Yeo, D., van Zandwijk, N., & Rasko, J. E. J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00264-1 · Cited by 93 · see citing works
Lievense, L. A., Cornelissen, R., Bezemer, K., Kaijen-Lambers, M. E. H., Hegmans, J. P., & Aerts, J. G. J. V. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.021 · Cited by 86 · see citing works
Self-citationChéné, A.-L., d’Almeida, S., Blondy, T., Tabiasco, J., Deshayes, S., Fonteneau, J.-F., Cellerin, L., Delneste, Y., Grégoire, M., & Blanquart, C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.022 · Cited by 84 · see citing works
Belgiovine, C., Digifico, E., Anfray, C., Ummarino, A., & Andón, F. T. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103226 · Cited by 66 · see citing works
Prognostic significance of macrophage polarization in early stage oral squamous cell carcinomas
Weber, M., Iliopoulos, C., Möbius, P., Büttner-Herold, M. J., Amann, K., Ries, J., Preidl, R. H. M., Neukam, F. W., & Wehrhan, F. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.001 · Cited by 79 · see citing works
Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma
Minnema-Luiting, J., Vroman, H. H., Aerts, J. G. J. V., & Cornelissen, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041041 · Cited by 73 · see citing works
Self-citationThe Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Chu, G. J., van Zandwijk, N., & Rasko, J. E. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01366 · Cited by 70 · see citing works
Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma
Salaroglio, I. C., Kopecka, J., Napoli, F., Pradotto, M., Maletta, F., Costardi, L., Gagliasso, M., Milošević, V., Ananthanarayanan, P., Bironzo, P., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.029 · Cited by 70 · see citing works
Ngambenjawong, C., Cieslewicz, M., Schellinger, J. G., & Pun, S. H. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.057 · Cited by 69 · see citing works
Rehrauer, H., Wu, L., Blum, W., Pecze, L., Henzi, T., Serre‐Beinier, V., Aquino, C., Vrugt, B., de Perrot, M. E., Schwaller, B., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0153-z · Cited by 69 · see citing works
Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate
Pandey, A., Stawiski, E. W., Durinck, S., Gowda, H., Goldstein, L. D., Barbhuiya, M. A., Schröder, M., Sreenivasamurthy, S. K., Kim, S., Phalke, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17880-4 · Cited by 68 · see citing works
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Cantini, L., Hassan, R., Sterman, D. H., & Aerts, J. G. J. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00343 · Cited by 59 · see citing works
Self-citationTumor Immune Microenvironment and Genetic Alterations in Mesothelioma
Hiltbrunner, S., Mannarino, L., Kirschner, M. B., Opitz, I., Rigutto, A., Laure, A., Lia, M., Nozza, P., Maconi, A., Marchini, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.660039 · Cited by 56 · see citing works
Tong, B., & Wang, M. (2018) · Future Oncology · doi:10.2217/fon-2018-0035 · Cited by 55 · see citing works
Bononi, A., Napolitano, A., Pass, H. I., Yang, H., & Carbone, M. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.1081066 · Cited by 54 · see citing works
Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma
Blondy, T., D'Almeida, S. M., Briolay, T., Tabiasco, J., Meiller, C., Chené, A., Cellerin, L., Deshayes, S., Delneste, Y., Fonteneau, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000182 · Cited by 53 · see citing works
CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy
Magkouta, S., Vaitsi, P. C., Pappas, A., Iliopoulou, M. P., Kosti, C., Psarra, K., & Kalomenidis, I. (2021) · Cancers · doi:10.3390/cancers13112546 · Cited by 52 · see citing works
Biological functions and theranostic potential of HMGB family members in human cancers
Niu, L., Yang, W., Duan, L., Wang, X., Li, Y., Xu, C., Liu, C., Zhang, Y., Zhou, W. J., Liu, J., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920970850 · Cited by 51 · see citing works
Malignant pleural mesothelioma: an update
Hajj, G. N. M., Cavarson, C. H., Pinto, C. A. L., Venturi, G., Navarro, J. R., & de Lima, V. C. C. (2021) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210129 · Cited by 48 · see citing works
Harber, J., Kamata, T., Pritchard, C. A., & Fennell, D. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003032 · Cited by 47 · see citing works
Immunoprofiling as a predictor of patient’s response to cancer therapy—promises and challenges
Bethmann, D., Feng, Z., & Fox, B. A. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.005 · Cited by 46 · see citing works
Zhu, P., #x2019, #x2019, Lu, H., Wang, M., Chen, K., Chen, Z., & Yang, L. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0491 · Cited by 44 · see citing works
Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
Cersosimo, F., Barbarino, M., Lonardi, S., Vermi, W., Giordano, A., Bellan, C., & Giurisato, E. (2021) · Cancers · doi:10.3390/cancers13225664 · Cited by 41 · see citing works
Abbott, D. M., Bortolotto, C., Benvenuti, S., Lancia, A., Filippi, A. R., & Stella, G. M. (2020) · Cancers · doi:10.3390/cancers12051186 · Cited by 40 · see citing works
The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021) · Cancers · doi:10.3390/cancers13133205 · Cited by 34 · see citing works
Eguchi, T., Kadota, K., Mayor, M., Zauderer, M. G., Rimner, A., Rusch, V. W., Travis, W. D., Sadelain, M., & Adusumilli, P. S. (2017) · Oncotarget · doi:10.18632/oncotarget.20845 · Cited by 34 · see citing works
Biomarkers for Malignant Pleural Mesothelioma—A Novel View on Inflammation
Vogl, M., Rosenmayr, A., Bohanes, T., Scheed, A., Brndiar, M., Stubenberger, E., & Ghanim, B. (2021) · Cancers · doi:10.3390/cancers13040658 · Cited by 33 · see citing works
Biological Basis for Novel Mesothelioma Therapies
Obacz, J., Yung, H., Shamseddin, M., Linnane, E., Liu, X., Azad, A. A., Rassl, D. M., Fairen-Jimenez, D., Rintoul, R. C., Nikolić, M. Z., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01462-2 · Cited by 31 · see citing works
Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion
Bertino, P., Premeaux, T. A., Fujita, T., Haun, B. K., Marciel, M. P., Hoffmann, F. W., Garcia, A. L., Yiang, H., Pastorino, S., Carbone, M., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1601482 · Cited by 29 · see citing works
Chen, R., Lee, W., Fujimoto, J., Li, J., Hu, X., Mehran, R. J., Rice, D. C., Swisher, S. G., Sepesi, B., Tran, H. T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1767 · Cited by 29 · see citing works
Marqués, M., Tranchant, R., Risa-Ebrí, B., Suárez-Solís, M. L., Fernández, L. C., Pau, E. C. D. S., del Pozo, N., de Villarreal, J. M., Meiller, C., Allory, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1633 · Cited by 28 · see citing works
Cornelissen, R., Lievense, L. A., Robertus, J. L., Hendriks, R. W., Hoogsteden, H. C., Hegmans, J. P., & Aerts, J. G. J. V. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.03.013 · Cited by 27 · see citing works
Self-citationSerum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients
Kishimoto, T., Fujimoto, N., Ebara, T., Omori, T., Oguri, T., Niimi, A., Yokoyama, T., Kato, M., Usami, I., Nishio, M., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6419-1 · Cited by 25 · see citing works
Tolani, B., Acevedo, L. A., Hoang, N. T., & He, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010238 · Cited by 20 · see citing works
A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma
de Fonseka, D., Arnold, D., Stadon, L. J., Morley, A., Keenan, E. K., Darby, M. J., Armstrong, L., Virgo, P., & Maskell, N. A. (2018) · BMC Cancer · doi:10.1186/s12885-018-4113-3 · Cited by 20 · see citing works
Lievense, L. A., Bezemer, K., Cornelissen, R., Kaijen-Lambers, M. E. H., Hegmans, J. P., & Aerts, J. G. J. V. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.015 · Cited by 19 · see citing works
Self-citationYe, L., Ma, S., Robinson, B. W. S., & Creaney, J. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1563488 · Cited by 18 · see citing works
Gaw, S. L., Hromatka, B. S., Ngeleza, S., Buarpung, S., Özarslan, N., Tshefu, A. K., & Fisher, S. J. (2019) · Malaria Research and Treatment · doi:10.1155/2019/1378174 · Cited by 18 · see citing works
Al-Taei, S., Salimu, J., Spary, L. K., Clayton, A., Lester, J. F., & Tabi, Z. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1268308 · Cited by 17 · see citing works
Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
Wadowski, B. J., Bueno, R., & Rienzo, A. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684025 · Cited by 17 · see citing works
The Current Treatment Landscape of Malignant Pleural Mesothelioma and Future Directions
Bertin, B., Zugman, M., & Schvartsman, G. (2023) · Cancers · doi:10.3390/cancers15245808 · Cited by 16 · see citing works
Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
Terenziani, R., Zoppi, S., Fumarola, C., Alfieri, R. R., & Bonelli, M. A. (2021) · Cancers · doi:10.3390/cancers13112793 · Cited by 16 · see citing works
Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies
Hinz, T. K., & Heasley, L. E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.014 · Cited by 15 · see citing works
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream
Calabrò, L., Bronte, G., Grosso, F., Cerbone, L., Delmonte, A., Nicolini, F., Mazza, M., Giacomo, A. M. D., Covre, A., Lofiego, M. F., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1333661 · Cited by 14 · see citing works
Guo, Y., Xu, C., Fang, Y., Wang, C., Gao, N., Wen, Q., & Qiao, H. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23029 · Cited by 13 · see citing works
Hojo, M., Yamamoto, Y., Sakamoto, Y., Maeno, A., Ohnuki, A., Suzuki, J., Inomata, A., Moriyasu, T., Taquahashi, Y., Kanno, J., et al. (2021) · Cancer Science · doi:10.1111/cas.14873 · Cited by 10 · see citing works
Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition
Cantini, L., Laniado, I., Murthy, V., Sterman, D. H., & Aerts, J. G. J. V. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.016 · Cited by 10 · see citing works
Self-citationTada, A., Minami, T., Kitai, H., Higashiguchi, Y., Tokuda, M., Higashiyama, T., Negi, Y., Horio, D., Nakajima, Y., Otsuki, T., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107219 · Cited by 9 · see citing works
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences
Calabrò, L., Ceresoli, G. L., D’Incecco, A., Scherpereel, A., Aerts, J. G. J. V., & Maio, M. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.07.003 · Cited by 9 · see citing works
Self-citationPrognostic Role of Tumor Immune Microenvironment in Pleural Epithelioid Mesothelioma
Ollila, H., Mäyränpää, M. I., Paavolainen, L., Paajanen, J., Välimäki, K. E., Sutinen, E., Wolff, H. J., Räsänen, J. V., Kallioniemi, O., Myllärniemi, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.870352 · Cited by 8 · see citing works
Novel immunotherapy clinical trials in malignant pleural mesothelioma
Tano, Z. E., Chintala, N. K., Li, X., & Adusumilli, P. S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.81 · Cited by 8 · see citing works
Fuchs, T. L., Chou, A. S. Y., Sioson, L., Sheen, A., & Gill, A. J. (2020) · Histopathology · doi:10.1111/his.14106 · Cited by 8 · see citing works
Brčić, L., Mathilakathu, A., Walter, R. F. H., Wessolly, M., Mairinger, E., Beckert, H., Kreidt, D., Steinborn, J., Hager, T., Christoph, D. C., et al. (2021) · Cancers · doi:10.3390/cancers13081761 · Cited by 7 · see citing works
What can independent research for mesothelioma achieve to treat this orphan disease?
Guazzelli, A., Meysami, P., Bakker, E. Y., Bonanni, E., Demonacos, C., Krstic–Demonacos, M., & Mutti, L. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1638363 · Cited by 7 · see citing works
Ferrara, R., Signorelli, D., Proto, C., Prelaj, A., Garassino, M. C., & Russo, G. L. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-636 · Cited by 7 · see citing works
New horizons from immunotherapy in malignant pleural mesothelioma
Calabrò, L., Rossi, G., & Maio, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.88 · Cited by 6 · see citing works
Zhou, M. Y., Joshi, N., Raj, K. P., Wakelee, H. A., & Neal, J. W. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.05.012 · Cited by 6 · see citing works
Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment
Carreira, B., Acúrcio, R. C., Matos, A. I., Peres, C., Pozzi, S., Vaskovich‐Koubi, D., Kleiner, R., Bento, M., Satchi‐Fainaro, R., & Florindo, H. F. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000147 · Cited by 6 · see citing works
Cheng, L., Li, N., Xu, X., & Mao, W. (2020) · Current Drug Targets · doi:10.2174/1389450121666200719011234 · Cited by 5 · see citing works
Microenvironment and Immunology of the Human Pleural Malignant Mesothelioma
Digifico, E., Belgiovine, C., Mantovani, A., & Allavena, P. (2019) · Springer eBooks · doi:10.1007/978-3-030-16884-1_5 · Cited by 5 · see citing works
PI3Kγ in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target
Luo, Q., Fortune, A., & Lane, A. A. (2025) · Blood · doi:10.1182/blood.2024027376 · Cited by 3 · see citing works
Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival
Zhang, L., & Huang, M. (2025) · MedComm · doi:10.1002/mco2.70327 · Cited by 3 · see citing works
de Arruda, J. A. A., Arantes, D. A. C., Schuch, L. F., Abreu, L. G., de Andrade, B. A. B., Romañach, M. J., Mesquita, R. A., Watanabe, S., de Oliveira, J. C., & Mendonça, E. F. (2020) · Head and Neck Pathology · doi:10.1007/s12105-020-01242-z · Cited by 3 · see citing works
Wang, Y., & Guo, J. (2020) · PeerJ · doi:10.7717/peerj.9996 · Cited by 3 · see citing works
Delsignore, M., Cassinari, G., Revello, S., Cerbone, L., Grosso, F., Arsura, M., & Porta, C. (2025) · Cancers · doi:10.3390/cancers17244020 · Cited by 2 · see citing works
Immune reaction by cytoreductive prostatectomy.
Lee, G. T., Srivastava, A., Kwon, Y. S., & Kim, I. Y. (2019) · PubMed Central · Cited by 2 · see citing works
Cantini, L., Pecci, F., Merloni, F., Lanese, A., Lenci, E., Paoloni, F., Aerts, J. G. J. V., & Berardi, R. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00030 · Cited by 2 · see citing works
Self-citationHirose, Y., Kaida, H., Kawahara, A., Matono, S., Tanaka, T., Kurata, S., Kage, M., Ishibashi, M., & Abe, T. (2016) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000550 · Cited by 2 · see citing works
Blanquart, C., & Scherpereel, A. (2026) · Thorax · doi:10.1136/thorax-2025-223284 · Cited by 1 · see citing works
Rigutto, A., Núñez, N. G., Kienzler, J. C., Opitz, I., Meerang, M., Haberecker, M., Fournier, N., Lourenço, J., Gottardo, R., Siliņa, K., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03421-1 · Cited by 1 · see citing works
Sakharov, V. N., & Litvitskiy, P. F. (2015) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn.v70.i4.1417 · Cited by 1 · see citing works
Mesothelioma Heterogeneity: Potential Mechanisms
Felley-Bosco, E. (2019) · MDPI eBooks · doi:10.3390/books978-3-03897-474-1 · Cited by 1 · see citing works
Tissue and Circulating Biomarkers in Mesothelioma
Zucali, P. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-16884-1_8
Pasello, G., Felley‐Bosco, E., & Remon, J. (2022) · Frontiers research topics · doi:10.3389/978-2-88974-818-1
Weng, J., & Chen, J. (2023) · Medicine · doi:10.1097/md.0000000000035579
Duong, L., Jackaman, C., & Nelson, D. J. (2024) · Ageing and Cancer Research & Treatment · doi:10.70401/acrt.2025.0012
Koç, T., Yüceer, R. O., ALTAY, T., Taş, N., & ÇELİKGÜN, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156961
- Authors
- Cornelissen, R., Lievense, L. A., Maat, A. P., Hendriks, R. W., Hoogsteden, H. C., Bogers, A. J., Hegmans, J. P., & Aerts, J. G.
- Affiliations
- Erasmus MC Cancer Institute (NL)
- Corresponding author
- Aerts, Joachim G.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-09-05
- Volume
- 9
- Issue
- 9
- Pages
- e106742
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4156398
- OpenAlex
- W2045012199
- Cited by
- 91
- References
- 49
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 3 · 2021: 15 · 2020: 15 · 2019: 12 · 2018: 8 · 2017: 7 · 2016: 8 · 2015: 7 · 2014: 2
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Mesothelioma Applied Research Foundation
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- malignant pleural mesothelioma, epithelioid mesothelioma, tumor-associated macrophages, M2 macrophages, prognostic factors, tumor microenvironment, macrophage polarization, CD8+ T cells, overall survival, surgical treatment
- MeSH terms
- Mesothelioma, Malignant, CD68 Molecule, CD163 Antigen, Adult, Aged, Antigens, Surface, Female, Humans, Lung Neoplasms, Macrophages, Male, Mesothelioma, Middle Aged, Neoplasm Staging, Phenotype, Pleural Neoplasms, Prognosis, Receptors, Cell Surface, Antigens, Differentiation, Myelomonocytic, Antigens, CD, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
